Aptahem AB (publ) (APTA.ST)
SEK 1.14
(-0.87%)
SEK 1.14
(-0.87%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 2.63 Million SEK | 3636.97% |
| 2022 | -71.78 Thousand SEK | -16.22% |
| 2021 | -61.76 Thousand SEK | 16.32% |
| 2020 | -73.8 Thousand SEK | -0.0% |
| 2019 | -73.8 Thousand SEK | 99.64% |
| 2018 | -20.59 Million SEK | -101.53% |
| 2017 | -10.21 Million SEK | -4.95% |
| 2016 | -9.73 Million SEK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 419 Thousand SEK | -26.93% |
| 2024 Q1 | 609 Thousand SEK | 2536.0% |
| 2023 FY | -91.81 Thousand SEK | -27.91% |
| 2023 Q2 | -23 Thousand SEK | 0.0% |
| 2023 Q3 | -23 Thousand SEK | 0.0% |
| 2023 Q4 | -25 Thousand SEK | -8.7% |
| 2023 Q1 | -23 Thousand SEK | 0.0% |
| 2022 Q2 | -15 Thousand SEK | 0.0% |
| 2022 FY | -71.78 Thousand SEK | -16.22% |
| 2022 Q4 | -23 Thousand SEK | -27.78% |
| 2022 Q3 | -18 Thousand SEK | -20.0% |
| 2022 Q1 | -15 Thousand SEK | 0.0% |
| 2021 Q3 | -15 Thousand SEK | 0.0% |
| 2021 FY | -61.76 Thousand SEK | 16.32% |
| 2021 Q2 | -15 Thousand SEK | 0.0% |
| 2021 Q4 | -15 Thousand SEK | 0.0% |
| 2020 FY | -73.8 Thousand SEK | -0.0% |
| 2019 FY | -73.8 Thousand SEK | 99.64% |
| 2018 FY | -20.59 Million SEK | -101.53% |
| 2017 FY | -10.21 Million SEK | -4.95% |
| 2016 FY | -9.73 Million SEK | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -160.68 Million SEK | 101.637% |
| Ziccum AB (publ) | -23.28 Million SEK | 111.297% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| BioArctic AB (publ) | 346.31 Million SEK | 99.24% |
| Sprint Bioscience AB (publ) | 41.78 Million SEK | 93.705% |
| Mendus AB (publ) | 28.48 Million SEK | 90.765% |
| Genovis AB (publ.) | 54 Million SEK | 95.129% |
| Intervacc AB (publ) | -13.79 Million SEK | 119.071% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 2.17 Million SEK | -21.172% |
| Active Biotech AB (publ) | -1.67 Million SEK | 257.054% |
| Magle Chemoswed Holding AB (publ) | 9.96 Million SEK | 73.596% |
| Bio-Works Technologies AB (publ) | 26.82 Million SEK | 90.192% |
| Vicore Pharma Holding AB (publ) | -3.42 Million SEK | 176.897% |
| Kancera AB (publ) | -1.96 Million SEK | 233.875% |
| Infant Bacterial Therapeutics AB (publ) | 77 Thousand SEK | -3316.426% |
| Fluicell AB (publ) | 1.73 Million SEK | -51.361% |
| Saniona AB (publ) | 11.78 Million SEK | 77.67% |
| Lipigon Pharmaceuticals AB (publ) | -5.11 Million SEK | 151.41% |
| Biovica International AB (publ) | 6.87 Million SEK | 61.747% |
| Spago Nanomedical AB (publ) | -23.28 Million SEK | 111.299% |
| AcouSort AB (publ) | 8.38 Million SEK | 68.642% |
| Xintela AB (publ) | 78 Thousand SEK | -3272.626% |
| Abliva AB (publ) | -35.66 Million SEK | 107.376% |
| Egetis Therapeutics AB (publ) | -146.9 Million SEK | 101.791% |
| Karolinska Development AB (publ) | 2.8 Million SEK | 6.283% |
| OncoZenge AB (publ) | 3000.00 SEK | -87588.267% |
| Amniotics AB (publ) | -1.93 Million SEK | 236.303% |
| 2cureX AB (publ) | -37.48 Million SEK | 107.017% |
| CombiGene AB (publ) | -21.29 Million SEK | 112.356% |
| Asarina Pharma AB (publ) | -423 Thousand SEK | 721.903% |
| Calliditas Therapeutics AB (publ) | 1.12 Billion SEK | 99.767% |
| Camurus AB (publ) | 1.58 Billion SEK | 99.834% |
| Corline Biomedical AB | 28.38 Million SEK | 90.731% |
| IRLAB Therapeutics AB (publ) | -122.73 Million SEK | 102.143% |
| Isofol Medical AB (publ) | -34.41 Million SEK | 107.644% |
| I-Tech AB | 27.56 Million SEK | 90.457% |
| Hansa Biopharma AB (publ) | 70.95 Million SEK | 96.292% |
| Cyxone AB (publ) | 2.61 Million SEK | -0.753% |
| ExpreS2ion Biotech Holding AB (publ) | 3.4 Million SEK | 22.696% |
| Biosergen AB | -456 Thousand SEK | 676.896% |
| Cantargia AB (publ) | -3.45 Million SEK | 176.229% |
| NextCell Pharma AB | -43.74 Million SEK | 106.013% |
| Xspray Pharma AB (publ) | -9.19 Million SEK | 128.613% |
| Elicera Therapeutics AB (publ) | 11.21 Million SEK | 76.55% |
| Nanologica AB (publ) | -76 Thousand SEK | 3561.379% |
| SynAct Pharma AB | -778 Thousand SEK | 438.13% |
| Annexin Pharmaceuticals AB (publ) | -193 Thousand SEK | 1463.03% |
| Stayble Therapeutics AB (publ) | - SEK | -Infinity% |
| LIDDS AB (publ) | -12.92 Million SEK | 120.358% |
| Lipum AB (publ) | 53 Thousand SEK | -4863.487% |
| BioInvent International AB (publ) | 71.46 Million SEK | 96.319% |
| Alzinova AB (publ) | 19.87 Million SEK | 86.763% |
| Oncopeptides AB (publ) | 36.29 Million SEK | 92.753% |
| Pila Pharma AB (publ) | 1.46 Million SEK | -79.809% |
| Guard Therapeutics International AB (publ) | -15 Thousand SEK | 17637.653% |
| Scandinavian ChemoTech AB (publ) | 1.65 Million SEK | -58.664% |
| Simris Alg AB (publ) | 2 Million SEK | -31.074% |
| Diamyd Medical AB (publ) | -3.58 Million SEK | 173.482% |
| Xbrane Biopharma AB (publ) | 35.38 Million SEK | 92.566% |
| Ascelia Pharma AB (publ) | -1.04 Million SEK | 350.777% |
| Diagonal Bio AB (publ) | 3.13 Million SEK | 16.034% |